| Literature DB >> 20735843 |
Surajita Banerjee1, Kamalesh Sarkar, Soma Gupta, Prasanta Sinha Mahapatra, Siddhartha Gupta, Samudra Guha, Debasis Bandhopadhayay, Chaitry Ghosal, Suman Kalyan Paine, Rathindra Nath Dutta, Nibir Biswas, Basudev Bhattacharya.
Abstract
BACKGROUND: Implementation of Multi drug Therapy (MDT) regimen has resulted in the decline of the total number of leprosy cases in the world. Though the prevalence rate has been declining, the incidence rate remains more or less constant and high in South East Asian countries particularly in India, Nepal, Bangladesh, Pakistan and Srilanka. Leprosy, particularly that of multibacillary type spreads silently before it is clinically detected. An early detection and treatment would help to prevent transmission in the community. Multiplex PCR (M-PCR) technique appears to be promising towards early detection among contacts of leprosy cases.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20735843 PMCID: PMC2942881 DOI: 10.1186/1471-2334-10-252
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Sensitivity of AFB and multiplex-PCR as diagnostic tools in detecting paucibacillary as well as multibacillary leprosy cases among clinically diagnosed patients
| Type of disease | Clinical Forms | Cases confirmed by AFB In SSS | Cases confirmed by Multiplex-PCR | Percent of positivity by AFB test | Percent of positivity of M-PCR test |
|---|---|---|---|---|---|
| Paucibacillary cases (n = 234) | TT (n = 140) | 44 (BI < 2) | 111 | 31.4% | 79.2% |
| BT (n = 94) | 18 (BI < 2) | 77 | 19.1% | 81.9% | |
| Total | 234 | 52 | 188 | 22.2% | 80.3% |
| Multibacillary cases (n = 205) | BL (n = 53) | 38 (BI > 2) | 47 | 71.6% | 88.6% |
| LL (n = 152) | 133 (BI > 2) | 136 | 87.5% | 89.4% | |
| Total | 205 | 171 | 183 | 83.4% | 89.2% |
Figure 1Sequencing report.
Showing M-PCR positivity and incidence of leprosy in household contacts of leprosy cases in nasal swabs
| Multibacillary leprosy contact | Paucibacillary leprosy contact | ||||
|---|---|---|---|---|---|
| Adult = 68 | 8 (11.7%) | 1 | Adult = 48 | 1 (2%) | 0 |
| Child = 42 | 4 (9.5%) | 1 | Child = 24 | 0 (0%) | 0 |
| Total = 110 | 12 (10.9%) | 2 | Total = 72 | 1 (1.3%) | 0 |
Sensitivity of AFB and multiplex-PCR as diagnostic tools in detecting multibacillary leprosy cases among different categories of multibacillary patients
| BL n = 53 | |||||
|---|---|---|---|---|---|
| Clinical status of the disease | Cases confirmed by AFB In SSS(Slit skin smear) | Cases confirmed by Multiplex-PCR | Percent of positivity by AFB test | Percent of positivity of M-PCR test | |
| BI | No of case | ||||
| Patients without treatment (New Cases)(n = 44) | 2 | 23 | 23 | 100% | 100% |
| 3 | 11 | 11 | |||
| 4 | 10 | 10 | |||
| Patients on treatment not more than 2 months (n = 5) | 0 | 4 | 2(50%) | 25% | 60% |
| 2 | 1 | 1 | |||
| 3 | 0 | 0 | |||
| 4 | 0 | 0 | |||
| Patients released from treatment (RFT)(a)/later developed a new active lesion/relapsed cases(b) (n = 4) | 0 | 2a, | 2(0%) | 50% | 50% |
| 2 | 1a | 1a | |||
| 3 | 1b | 1b | |||
| Total n = 53 | 71.6% (38/53) | 88.67% (47/53) | |||
| LL n = 152 | |||||
| Patients without treatment (New Cases)(n = 115) | 2 | 8 | 8 | 100% | 100% |
| 3 | 35 | 35 | |||
| 4 | 37 | 37 | |||
| 5 | 31 | 31 | |||
| 6 | 4 | 4 | |||
| Patients on treatment not more than 2 months (n = 12) | 0 | 4 | 1(25%) | 66.66% | 75% |
| 2 | 3 | 3 | |||
| 3 | 2 | 2 | |||
| 4 | 3 | 3 | |||
| 5 | 0 | 0 | |||
| 6 | 0 | 0 | |||
| Patients released from treatment (RFT)(a)/later developed a new active lesion/relapsed cases(b) (n = 25) | 0 | 14a,1b | 2(13.33%) | 40% | 48% |
| 2 | 1a,2b | 3 | |||
| 3 | 2b | 2 | |||
| 4 | 2a,1b | 3 | |||
| 5 | 1a | 1 | |||
| 6 | 1a | 1 | |||
| Total n = 152 | 83.4% (133/152) | 89.2% (136/152) | |||
Sensitivity of AFB and multiplex-PCR as diagnostic tools in detecting paucibacillary as well as multibacillary leprosy cases among different categories of paucibacillary patients
| Clinical status of the disease | Cases confirmed by AFB In SSS(Slit skin smear) | Cases confirmed by Multiplex-PCR | Percent of positivity by AFB test | Percent of positivity of M-PCR test | |
|---|---|---|---|---|---|
| BI | No of case | ||||
| Patients without treatment (New Cases)(n = 128) | 0 | 85 | 62 (72.9%) | 50.58% | 82% |
| 1 | 43 | 43 | |||
| Patients on treatment not more than 2 months (n = 7) | 0 | 6 | 3 (50%) | 14.28% | 57.14% |
| 1 | 1 | 1 | |||
| Patients released from treatment (RFT)(a)/later developed a new active lesion/relapsed cases(b) (n = 3) | 0 | 3a | 1a (33.3%) | 0% | 33.33% |
| 1 | 0 | 0 | |||
| Patients complaining of hypoesthesia but showing no clinical symptoms of leprosy - considered as Indeterminate type(n = 2) | 0 | 2 | 1 (50%) | 0% | 50% |
| 1 | 0 | 0 | |||
| Total n = 140 | 31.4% (44/140) | 79.2% (111/140) | |||
| BT n = 94 | |||||
| Patients without treatment (New Cases)(n = 85) | 0 | 68 | 55 (80.8%) | 20% | 84.70% |
| 1 | 17 | 17 | |||
| Patients on treatment not more than 2 months (n = 6) | 0 | 5 | 2(40%) | 16.6% | 50% |
| 1 | 1 | 1 | |||
| Patients released from treatment (RFT)(a)/later developed a new active lesion/relapsed cases(b) (n = 3) | 0 | 2a, 1b | 1a,1b (33.33%) | 0% | 66.6% |
| 1 | 0 | 0 | |||
| Total n = 94 | 19.14% (18/94) | 81.9% (77/94) | |||
TT (including 2 indeterminates) n = 138 + 2 Indeterminate